Disease Staging-related Imaging Biomarker Detection Service
Disease staging plays a key role in the clinical treatment and management of diseases. Medical imaging technology is one of the important technical means of disease staging. Imaging biomarkers have development prospects and potential in the related research of disease staging. As an expert in the field of biomarkers, in addition to providing single biomarker detection services and multiple biomarker detection services, Creative BioMart Biomarker also provides scientific research outsourcing services for imaging biomarker research, helping customers advance research projects in the field of disease staging.
Introduction
Disease staging is a method used clinically for disease management, which refers to classifying diseases according to their severity. Disease staging is generally based on pre-defined medical standards to measure the severity of the disease. There are already hundreds of diseases that can be graded, and different stages represent the severity of the disease. The disease staging originated from the tumor stage at the earliest, and later the disease staging also applies to some diseases other than tumor. Most diseases, including tumors, are clinically staged, with more serious complications in the later stages of the disease, as well as a worse prognosis and treatment effect. The establishment of disease staging standards is based on the biological process of the disease and various complications such as infection, perforation, bleeding, shock, etc., to determine different stages of the disease. The disease staging generally includes four stages ranging from mild to severe. The first stage is suitable for diseases with no complications or the lowest severity. The second stage increases the risk of complications, but the disease is limited to the corresponding one organ. The third stage is multi-site participation, systemic participation, and poor prognosis of the organs or organ systems. The fourth stage is the most serious, including patients who have died. Disease staging is helpful for a clearer understanding of the development of the disease and the severity of the disease, and relevant information can be obtained clinically through imaging examination and pathological biopsy. Imaging techniques such as X-ray, ultrasound, magnetic resonance imaging (MRI), computed tomography (CT) and positron emission tomography (PET) can all be used in clinical staging of tumors to provide information on the location and spread of the primary tumor.
Application
Disease staging-related imaging biomarker detection service is applicable to the research of various diseases such as tumor and diabetic nephropathy.
Our Advantages
- Multiple imaging biomarkers detection technology platforms
- Ensure high accuracy and precision imaging biomarkers detection service
- Provide quantitative imaging biomarkers detection service
- Provide detailed professional analysis report
- Customized service scheme according to the specific needs
- Shorter service cycle and more competitive prices
- Experienced technical team
Workflow of Imaging Biomarker Detection at Creative BioMart Biomarker
At Creative BioMart Biomarker, we provide customers with high-quality imaging biomarker detection services related to disease staging. Customers can discuss with our expert team based on specific research needs or research objects, and we will work out the appropriate experimental plan as soon as possible. Our technical team has extensive experience in the field of imaging biomarkers, and has been strictly controlling every process in the imaging biomarker detection service to ensure that customers are provided with accurate test results. If you are seeking related services, Creative BioMart Biomarker may be your ideal choice, please feel free to contact us for more information.
References:
- Conklin, J. E.; et al. Disease staging: implications for hospital reimbursement and management. Health care financing review. 1984, 1984(Suppl): 13-22.
- Tredici, K. D.; Braak, B. To stage or not to stage. journal of general internal medicine. Current Opinion in Neurobiology. 2020, 61: 10-20.
